Insights about U.S. Stocks that landed in the Green-Zone during Wednesday’s trade, are depicted underneath:
Limelight Networks, Inc (NASDAQ:LLNW)’s shares picked up 8.85%, and closed at $3.69, hitting new 52-week high of $3.72.
Limelight Networks, Inc., declared that Coach Guitar has deployed the Limelight Orchestrate™ Content Delivery and Cloud Storage platform to support the corporation’s rapidly growing business.
Coach Guitar, a Manomaya SAS corporation based in France, provides millions of customers of any skill level with a unique method of learning to play songs on the guitar through downloaded video tutorials. Established in 2012, they have already had over 2.6 million downloads of their app. The corporation will use the Orchestrate platform to power more than 3,000 customer downloads every day, enabling fast and reliable delivery of content to a growing global customer base.
Coach Guitar selected Limelight because of its ability not only to meet existing delivery needs, but because it will be able to support the corporation and scale as it grows and expands its offerings.
“Coach Guitar’s service is unique – and it is resonating with students across the world,” said Kirby Wadsworth, chief marketing officer at Limelight. “With a model dependent entirely on fast and reliable digital content delivery to consumers, even the slightest decrease in performance could be devastating. I know, because I am a customer. When I am set up, plugged in, and ready to practice, I have no patience for slow downloads either.”
Limelight Networks (LLNW), a global leader in digital content delivery, empowers customers to better engage digital audiences by enabling them to manage and deliver digital content on any device, anywhere in the world.
Stage Stores Inc (NYSE:SSI), raised 8.54%, and closed at $21.22.
Stage Stores Inc. (SSI), stated financial results for the fourth quarter and fiscal year ended January 31, 2015.
Michael Glazer, President and Chief Executive Officer, stated, “We ended the year with strong sales growth and record earnings in the fourth quarter. We achieved a 6.4% comparable sales gain and saw 30% growth in our direct-to-consumer business. Our merchandise margins expanded significantly, inventories ended in terrific shape from both a level and content perspective, and our fourth quarter profitability grew 35%.”
2015 Guidance:
Sales are predictable to be in a range of $1,640-$1,675 million, assuming a flat to 2% raise in comparable sales. The Corporation plans to open two stores and close 10-20 stores.
Earnings per diluted share are predictable to be in a range of $1.20- $1.28.
Weighted average diluted shares for the year are predictable to be 32.7 million. The effective tax rate is estimated to be 37.6%.
Capital expenditures net of construction allowances from landlords for 2015 are predictable to be $75 million, contrast to $65 million in 2014.
Stage Stores, Inc. operates as a specialty department store retailer in the United States. The corporation operates its stores under the nameplates of Bealls, Goody’s, Palais Royal, Peebles, and Stage.
PhotoMedex Inc (NASDAQ:PHMD), enhanced 8.20%, and closed at $1.98. The company holds the market capitalization of 35.04M. The stock return on equity value is -12.60%, while return on assets value is -7.80%, in response to its return on investment value of -10.30%. Its 20-day moving average gained 16.68%, and the stock moved above 50-day moving average of 21.26%. The mean recommendation of analysts for this stock is 2.70.(where 1=Buy, 5=Sale).
Dynavax Technologies Corporation (NASDAQ:DVAX), rose 8.04%, and closed at $21.31, hitting new 52-week high of $21.93.
Dynavax Technologies Corporation (DVAX), declared that the independent Data and Safety Monitoring Board (DSMB) charged with periodically reviewing safety data from the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine, has accomplished its second prespecified review and has recommended that the study continue unchanged. The second DSMB review comprised of safety data for all enrolled subjects collected through the data cut-off in February. As of the cut-off, all ongoing subjects had received the second immunization (which was the last active dose for HEPLISAV-B subjects) and all had reached at least 5 months follow-up after the first immunization. The DSMB reviewed unblinded tables and listings presenting key safety data. Based on this review, the panel recommended ongoing HBV-23 with no change to the study.
Dynavax, a clinical-stage biopharmaceutical corporation, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax’s lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine.
